noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Healthcare

The eRulemaking Program

Stage Distribution of SEER Incidence Cases, 2011-2020 By[...]
The eRulemaking Program

Concepts, Methods and Data Sources for Cumulative Health Risk[...]
The eRulemaking Program

Relative Survival Rates by Time Since Diagnosis, 2000-2019 by Age,[...]

Gilead Sciences Inc.

03/28/2024 | Press release | Distributed by Public on 03/28/2024 05:03

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

Sharing and Personal Tools

Please select the service you want to use:

Smartlinks | Gilead Sciences Inc. | News | Health | Local News | Company News | Top Company News | Business Announcement | Licensing Agreement | Pharmaceuticals | Securities Issuers | Pharmaceutical Companies | Borsa Italiana | London Stock Exchange (LSE) | Frankfurt Stock Exchange | Six Swiss Exchange | Sao Paulo Stock Exchange (B3) | Vienna Stock Exchange (ATX) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Hamburg Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Santiago Stock Exchange | Bolsa Mexicana de Valores (BMV) | BX Swiss | Tradegate Exchange | XETRA | NYSE American | NYSE ARCA Equities | Bolsa Electrónica de Chile | Nasdaq Global Select Market | Cboe BZX Exchange | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | Bolsa Institucional de Valores (BIVA) | Hannover Stock Exchange | Nasdaq BX | Nasdaq PSX | NYSE Chicago | Turquoise

Back